Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
Increasing Incidence and Prevalence of Microscopic Colitis in Sweden: A Nationwide Population-Based Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bergman David, Bozorg Soran R, Forss Anders, Sun Jiangwei, Marxer Carole A, Pardi Darrell S, Ludvigsson Jonas F
Аннотация
BACKGROUND & AIMS: There are few population-based studies on the incidence and prevalence of microscopic colitis (MC). The aim of this study was to assess incidence and prevalence of MC in Sweden.
METHODS: This was a nationwide population-based cohort study including all incident cases of biopsy-confirmed MC and all biopsied cases with normal mucosa from 1995 to 2021. Incidence rates (IRs) were age-standardized to the 2021 Swedish population. Age-specific IRs were plotted by sex. Poisson regression estimated trends and female-to-male incidence rate ratios. A combined model of MC and normal mucosa evaluated whether changes in MC incidence exceeded background biopsy trends. Point prevalence on December 31, 2021, was derived by dividing MC cases with population denominators. Lifetime risk was computed using a competing-risk cumulative incidence estimator.
RESULTS: We identified 22,519 incident MC cases (71% women) from 1995 to 2021. The mean age-standardized IR across the study period was 8.8 cases per 100,000 person-years (95% confidence interval [CI], 7.1-10.5) and rose steeply from 1995 until 2007 (+17% per year; 95% CI, 1.15-1.19), then increased more modestly (+3%; 95% CI, 1.02-1.04). The incidence of MC increased faster than that of normal mucosa; the mean difference was 4.33% per year (95% CI, 3.19-5.48). The prevalence of MC was 170 per 100,000 inhabitants in 2021. Lifetime risk was 1 in 54 for women and 1 in 133 for men.
CONCLUSIONS: In Sweden, incidence and prevalence of MC continued to rise through 2021. The steeper slope of MC incidence in relation to normal mucosa indicates either a true rise in disease occurrence or an ongoing diagnosis of prevalent cases related to an increased awareness of MC.
METHODS: This was a nationwide population-based cohort study including all incident cases of biopsy-confirmed MC and all biopsied cases with normal mucosa from 1995 to 2021. Incidence rates (IRs) were age-standardized to the 2021 Swedish population. Age-specific IRs were plotted by sex. Poisson regression estimated trends and female-to-male incidence rate ratios. A combined model of MC and normal mucosa evaluated whether changes in MC incidence exceeded background biopsy trends. Point prevalence on December 31, 2021, was derived by dividing MC cases with population denominators. Lifetime risk was computed using a competing-risk cumulative incidence estimator.
RESULTS: We identified 22,519 incident MC cases (71% women) from 1995 to 2021. The mean age-standardized IR across the study period was 8.8 cases per 100,000 person-years (95% confidence interval [CI], 7.1-10.5) and rose steeply from 1995 until 2007 (+17% per year; 95% CI, 1.15-1.19), then increased more modestly (+3%; 95% CI, 1.02-1.04). The incidence of MC increased faster than that of normal mucosa; the mean difference was 4.33% per year (95% CI, 3.19-5.48). The prevalence of MC was 170 per 100,000 inhabitants in 2021. Lifetime risk was 1 in 54 for women and 1 in 133 for men.
CONCLUSIONS: In Sweden, incidence and prevalence of MC continued to rise through 2021. The steeper slope of MC incidence in relation to normal mucosa indicates either a true rise in disease occurrence or an ongoing diagnosis of prevalent cases related to an increased awareness of MC.